natgillin/translations-raw huggingface dataset:
A pharmaceutical composition of claim 13 further comprising one to three additional therapeutic agents, optionally wherein the one to three one additional therapeutic agents is an anti-HIV agent, optionally wherein the one to three additional therapeutic agents is selected from the group consisting of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, and combinations thereof; or 
jedan do tri dodatna terapeutska sredstva, proizvoljno pri čemu je jedno do tri dodatna terapeutska sredstva sredstvo protiv HIV-a, proizvoljno pri čemu je jedno do tri dodatna terapeutska sredstva izabrano iz skupine koju čine inhibitori HIV proteaze, HIV nenukleozidni inhibitori reverzne transkriptaze, HIV nukleozidni ili nukleotidni inhibitori reverzne transkriptaze, i njihove kombinacije; ili ii) prvo dodatno terapeutsko sredstvo izabrano iz skupine koju čine: abakavir sulfat, tenofovir, tenofovir dizoproksil fumarat, tenofovir alafenamid, i tenofovir alafenamid hemifumarat i drugo terapeutsko sredstvo izabrano iz skupine koju čine emtricitibin i lamivudin.
The process according to claim 25, characterized in that the sanitary fixture to which the adhesive hygienizing composition is applied is wet, preferably following a discharge of water effected before the application of the composition. 
Postupak prema zahtjevu 23, naznačen time što je površina sanitarije mokra nakon ispuštanja vode prije nanošenja sredstva.
The bed arrangement of claim 8, wherein in the parameter setting mode, the set of predefined lying positions is definable and/or re-definable. 
Krevet u skladu s patentnim zahtjevom 7, naznačen time što je u načinu podešavanja parametara skup unaprijed definiranih ležećih položaja moguće definirati i/ili ponovno definirati.
is hydrogen or methyl; 
R je vodik ili metil;
Male Sprague Dawley rats (Charles River) weighing 250-275 g were made diabetic by a single intraperitoneal injection of streptozotocin (Sigma) at 65 mg/kg, prepared in fresh cold (4°C) 0.01 M citrate buffer. 
Mužjaci Sprague Dawley štakora (Charles River) tjelesne težine 250-275 g napravljeni su dijabetičnim jednom intraperitonealnom injekcijom streptozotocina (Sigma) u 65 mg/kg, koja je pripremljena u svježem hladnom (4"C) 0.01 M citratnom puferu.
The solution was cooled down to 20 °C and aged at this temperature until a seed bed formed (10 min to 1 h). 
Otopina je ohlađena do 20%C i ostavljena na ovoj temperaturi, dok se nije formirala klica kristala (10 min do 1 h).
with the variables as defined in claim 1; reacting an intermediate of formula (VIII) with lithium aluminium hydride in a suitable solvent, to obtain compounds of formula (I) wherein s is 1, herein referred to as compounds of formula (I-d) 
(I-c) sa varijablama kako je definirano u zahtjevu I; e) reakciju intermedijera prema formuli (VIII) sa litij aluminij hidridom u prikladnom otapalu, da se dobiju spojevi prema formuli (1) pri čemu s je 1, ovdje se nazivaju spojevi formule (I-d)
Such a mammal preferably has, is suspected of having, is at risk for developing, or has been diagnosed with at least a first retinal disorder, disease, or dystrophy, including, for example, Leber congenital amaurosis-1 (LCA-1), or wherein the mammal is at risk for developing, or has been diagnosed with one or more deficiencies, defects, or absence of biologically-active, functional guanylate cyclase protein, peptide, or polypeptide. 
Vektor prema bilo kojem od zahtjeva 1 do 8 ili pripravak prema zahtjevu 9 naznačen time da se koristi u postupku za prevenciju, liječenje ili ublažavanje bolesti, disfunkcije, poremećaja, nedostatka ili abnormalnog stanja kod sisavca, ili jednog ili više od njihovih simptoma, pri čemu se kod sisavca sumnja da ima rizik za razvoj, ili mu je dijagnosticiran barem prvi poremećaj mrežnice, bolest ili distrofija.
The fabric softening composition of claim 1, wherein component B is selected from the group consisting of fatty acids and fatty acid monoesters of glycerol, diglycerol, triglycerol, sorbitol and sorbitan. 
Pripravak za omekšavanje tkanine prema zahtjevu 4, naznačen time da je komponenta B odabrana iz skupine koju čine masne kiseline i monoesteri masnih kiselina, monoesteri glicerola, diglicerola, triglicerola, sorbitola i sorbitana.
The solid is dried in a vacuum oven at 40 °C. 
(D)_Krutina se suši u vakuumskoj peći na 40%C.
An HIV gp140 trimer comprising an HIV gp140 polypeptide comprising an amino acid sequence at least 95% identical to the sequence and, comprising a trimerization domain; 
HIV gp140 trimer koji obuhvaća HIV gp140 polipeptid koji sadrži sekvencu aminokiselina najmanje 95% identično sekvenci:
reacting Compound 3 with a first aqueous base followed by neutralizing to obtain a primary SNS-595 hydrate; 
Mona ONO sa prvom vodenom bazom, nakon čega slijedi neutraliziranje da se dobije primarni SNS-595 hidrat;
Process according to claim 1, wherein structural elements are arranged inside the mold in order to facilitate the assembly of further elements to the finished product in order to make complex products. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da su strukturni elementi smješteni unutar kalupa kako bi se olakšalo sklapanje daljnjih elemenata na završeni proizvod radi izrade složenijih proizvoda.
Alternatively, a liposomal formulation is prepared by the method of U.S. Published Application No. 2003/0100511 (e.g. Examples 4 and 5) using a compound of this invention in place of compound 9 of that publication, and may be lyophilized as described in that publication. 
Alternativno, liposomalna formulacija pripravljena je metodom iz US objavljene prijave Br. 2003/0100511 (npr. Primjeri 4 1 5) upotrebom spoja iz ovog izuma umjesto spoja 9 1z prijave, i može se lipofilizirati kao što je opisano u prijavi.
The mouse of claim 35, wherein the Vk3-20/Jk1 gene sequence comprises a replacement of non-histidine codons designed to express histidines at positions 105, 106, 107, and 109 (according to IMGT numbering). 
(b) na položajima 105, 106, 107 1 109; ili (c) na položajima 106, 106 1 109; pri čemu su položaji navedeni prema IMGT numeraciji.
The pharmaceutical composition as claimed in claim 1, wherein the nebivolol hydrochloride is present in an amount of 0.5% to 10% w/w; the composition further comprises a diluent, a lubricant and a glidant; the diluent is present in an amount of 78% to 93.05% w/w; the lubricant is present in an amount of 0.25% to 3% w/w; and the glidant is present in an amount of 0.25% to 3% w/w; and optionally, the binder is present in an amount of 0.5% to 5% w/w and/or the disintegrant is present in an amount of 0.5% to 10% w/w. 
Farmaceutski pripravak prema patentnom zahtjevu 1, u kojem je nebivolol hidroklorid u rasponu od 0,5 % do 10 % w/w; razrjeđivač je u rasponu od 78 % do 93,05 % w/w; lubrikant je u rasponu od 0,25 % do 3 % w/w; a tvar za klizenje je u rasponu od 0,25 % do 3 % w/w; po izboru vezivo je u rasponu od 0,5 % do 5 % w/w; i/ili tvar za razgradnju je u rasponu od 0,5 % do 10 % w/w. oem Vremenska Krivulja Srednje Koncentracije u Plazmi [Nebivolol 5 mg. N=24]
Unit 50 samples this voltage signal, as in the preceding phases, and converts it into a digital value by means of the internal A/D converter, storing the maximum value thereof. 
Jedinica 50 uzorkuje ovaj naponski signal, kao u prethodnim fazama, i pomoću A/D pretvarača pretvara ga u digitalni signal, te sprema njegovu maksimalnu vrijednost.
The compound of claim 1 or 2, wherein the modified oligonucleotide comprises at least one modified nucleobase, optionally wherein the modified nucleobase is a 5-methylcytosine. 
b najmanje jedan nukleozid sadrži modificiranu nukleobazu, opcionalno gdje je modificirana nukleobaza 5-metilcitozin; c konjugatna grupa je povezana sa modificiranim oligonukleotidom na:
A method according to Claim 1 wherein the CO2 concentration is either 4.0 to 9.0% or 5.5 to 8.5%. 
Postupak u skladu s patentnim zahtjevom 1, pri čemu je koncentracija CO2 ili 4.0 do 9.0% ili 5.5 do 8.5%.
The compound according to item 2 wherein A is selected from the group consisting of 
Spoj u skladu s patentnim zahtjevom 2, jo time, da je A odabran iz skupine koja se sastoji od
a cannula (18) attached to the distal end of the body; a fiber optic cable extending through the hollow body, the fiber optic cable having a fiber optic (16) extending through the cannula (18); and 
HR P20110506 T1 PATENTNI ZAHTJEVI Oftalmološka sonda (10), koja obuhvaća: a) osnovno šuplje tijelo (12); b) kanilu (18) prikačenu na udaljenom kraju tijela;
The electrochemical cell electrolyte according to any of the preceding claims, wherein the electrolyte additive is selected from the group comprising vinylene carbonate, vinyl ethylene carbonate, propane sultone, N-containing heterocycles and aminated aromatic compounds. 
Elektrolit za elektrokemijski članak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se elektrolitni aditiv bira iz skupine koju čine vinilen-karbonat, vinil-etilen-karbonat, propan-sulton, heterocikli s N atomom i aminirani aromatski spojevi.
The pharmaceutically acceptable liquid composition of claim 1 or 2, wherein said pharmaceutically acceptable salt of ascorbic acid is ascorbate, Na-ascorbate, calcium ascorbate, potassium ascorbate, ascorbyl palmitate, or ascorbyl stearate. 
Farmaceutski prihvatljiv tekući sastav iz zahtjeva 1 ili 2, naznačeno time da spomenuta farmaceutski prihvatljiva sol askorbinske kiseline je askorbat, natrijev askorbat, kalcijev askorbat, kalijev askorbat, askorbil palmitat, ili askorbil stearat.
an aqueous solution comprising aluminum hydroxide wherein the concentration of the aluminum hydroxide is between 0.065% w/v to 1.0% w/v; 
(ili) vodena otopina koja sadrži aluminijev hidroksid, gdje je koncentracija aluminijevog hidroksida od 0,065% do 1,0% masa/volumen;
alkylating a compound of formula with R1-I in the presence of NaH or Cs2CO3 in DMF to a compound of formula wherein R1 is lower alkyl and the remaining substituents are described above, or if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts. 
HR P20191139 T1 R I pri čemu R' je niži alkil, a preostali supstituenti su opisani gore, ili ako je potrebno, pretvaranje dobivenih spojeva u farmaceutski prihvatljive kiselinske adicijske soli.
The column was washed by 20 ml of PBS and the bound material was eluted using elution buffer containing 35% propylene glycol in 20 mM phosphate pH 8.4. 
Kolona je isprana sa 20 ml PBS-a 1 vezani je materijal eluiran sa puferom za eluaciju koji je sadržavao 35% propilen glikola u 20 mM fosfatu pH 8.4.
a monoclonal antibody that binds to an epitope comprising residues 82-87 of the human CD40 sequence shown in SEQ ID NO:10 or SEQ ID NO:12; 
aminokiselinske ostatke regije koja određuje komplementarnost (CDR) u SEQ ID NO:6 i aminokiselinske ostatke regije koja određuje komplementarnost (CDR) u SEQ ID NO:7.
These factions were discarded, since they contained only cell culture impurities. 
Ove frakcije su bile odbačene jer su sadržavale jedino nečistoće iz stanične kulture.
reacting 2,2-dimethyl-1,3 dioxolane-4-carbaldehyde of formula with a vinyl Grignard reagent, to obtain a compound of formula IIa in the form of diastereoisomeric mixture (S,R+R,R) 
"a dai mA S vinil Grignardovim reagensom, da bi se dobio spoj formule Ila u obliku dijastereoizomerne smjese (S, R+R,
a first storage portion (31), apt to store thermal energy received from the solar radiation and arranged at said side skirt (23) of said cavity (20); and 
- prvi dio za pohranu (31), prikladan za pohranu toplinske energije dobivene od sunčevog zračenja 1 postavljen na navedenu bočnu oplatu (23) navedene šupljine (20) 1
Method according to any one of claims 1 to 8, characterised in that a demasking step is performed on the AB-specific antibodies in the sample before contacting the sample with AB-aggregates, especially if IgM antibodies are detected. 
Postupak prema bilo kojem od zahtjeva 1 do 8, naznačen time, da se u uzorku provodi korak demaskiranja na Aß-specifičnim protutijelima, prije stavljanja u doticaj uzorka s Aß-agregatima, posebno ako su otkrivena IgM-protutijela.
Compound of formula I or a salt, a N-oxide or a salt of a N-oxide of this compound as claimed in any one of claims 1 to 6 for use in the treatment of psoriasis or atopic eczema. 
Spoj formule I prema zahtjevu 5, naznačen time, da se upotrebljava za liječenje bronhijalne astme, COPD-a, psorijaze ili atopičnog ekcema.
a C1-C4 alkanol solvent such as ethanol, for about 15 minutes, and then the aminocrotonate (III) is added. 
Cy-C2 alkanolnom otapalu, kao što je etanol, tijekom oko 15 minuta i tada se doda aminokrotonat (III).
Interferon-B-1a for use according to claim 6, wherein the titration package further comprises a vial adapter and wherein the delivery devices are syringes pre-filled with a diluent for said lyophilized interferon-B-1a. 
Interferon-B-1a, namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što titracijski paket dodatno sadrži adapter za bočice i što su naprave za unos šprice prethodno napunjene razrjeđivačem za navedeni liofilizirani interferon-B-1a.
Sealing of the capsule 200 prior to its being used is ensured by a first membrane or foil 208, which is bonded or welded onto and along said upper edge 209, and a second membrane or foil 210, which is in turn bonded or welded onto and along the lower edge 204 of the body 206 and extends to almost touch, or even to come into contact with, the free end of said serrated cylindrical wall 216 . 
Zatvaranje kapsule 200 prije njene upotrebe osigurava se najprije membranom ili folijom 208, pričvršćenom ili zavarenom na i uz navedeni gornji rub 209, te drugom membranom ili folijom 210, koja je pak pričvršćena ili zavarena na i uz donji rub 204 trupa 206 i pruža se toliko da gotovo dodiruje, ili čak dolazi u kontakt, sa slobodnim krajem navedene nazubljene valjkaste stijenke
The aqueous pharmaceutical suspension according to claim 7, wherein the benzyl alcohol is, by weight/volume (g/100 mL about 0.25% to about 1.00%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što benzil-alkohol iznosi, težinski/volumno (£/100 ml otprilike 0,25 % do otprilike 1,00 %,
A method of treating according to claim 31, wherein said neoplastic disease is leukemia, lymphomas, multiple myeloma, lung cancer, breast cancer, myelodysplastic syndrome, myeloproliferative disease, pancreatic cancer, liver cancer, stomach cancer, esophageal cancer, gastrointestinal stromal tumor, cervical cancer, ovarian cancer, uterine cancer, or melanoma. 
Sastav za upotrebu u postupku prema zahtjevu 20, naznačeno time da je spomenuta neoplastična bolest leukemija, limfomi, multipli mijelomi, rak pluća, rak dojke, mijelodsiplastični sindrom, mijeloproliferativna bolest, rak gušterače, rak jetre, rak želuca, rak jednjaka, gastrointestinalni stromalni tumor, rak grlića maternice, rak jajnika, rak maternice ili melanom.
As used herein, the term "insulating means applies to all materials which act primarily as insulators. 
Kako se ovdje koristi, termin "izolacijsko sredstvo" primjenjuje se na sve materijale koji djeluju prvenstveno kao izolatori.
Flash chromatography using 10-50% EtOAc/Hexanes afforded the desired intermediate 6 as pale yellow oil (0.627 g, 18%%). 
Flash kromatografija primjenom 10-50% EtOAc/heksana dala je željeni Intermedijer 6 kao blijedo žuto ulje (0.627 g, 18%).
Atherosclerosis is an active process initiated by a continuous damage of the vascular endothelium. 
Ateroskleroza je aktivan proces koji započinje s trajnom ozljedom vaskularnog endotela.
The method as claimed in claim 6, wherein said additional therapeutic agent is another antiviral agent. 
Spoj za uporabu prema zahtjevu 7 naznačen time što je navedeno dodatno terapeutsko sredstvo drugo antivirusno sredstvo.
Further provided is a package comprising (b) an M3 antagonist of the invention and (a) a B2 agonist for the simultaneous, concurrent, separate or sequential use in the treatment of a said respiratory disease. 
Također je omogućena proizvodnja paketa koji sadrži (b) M3 antagonist sukladno predmetnom izumu i (a) kortikosteroid za istovremenu, paralelnu, odvojenu ili seckvencijalnu uporabu u liječenju navedenih respiratornih bolcsti.
The device according to claim 11, further comprising first and second heat exchangers, wherein the first heat exchanger is provided for heating the drying gas and is connected to the inlet orifice and the outlet orifice of the drying chamber in order to form a drying gas circuit, and the second heat exchanger is provided for heating the torrefying gas and is connected to the inlet orifice and the outlet orifice of the torrefying chamber to form a torrefying gas circuit. 
Uređaj u skladu s patentnim zahtjevom 9, naznačen time što sadrži dva izmjenjivača topline, gdje prvi izmjenjivač topline služi za grijanje plina za sušenje i povezan je s ulaznim otvorom i izlaznim otvorom komore za sušenje kako bi se omogućilo kruženje plina za sušenje, a drugi izmjenjivač topline služi za grijanje plina za torefakciju i povezan je s ulaznim otvorom i izlaznim otvorom komore za torefakciju kako bi se omogućilo kruženje plina za torefakciju.
Clocked regulation of the amount of plaster paste 
TAKTIRANO REGULIRANJE KOLIČINE GIPSANE PASTE
Use of a compound of formula (Compound I, trans -1-((1 R,3 S)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine) or a salt thereof in the preparation of a medicament for the treatment of a disease selected from the group consisting of Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, and mania in bipolar disorder. 
Uporaba soli prema bilo kojem od zahtjeva 1-8 u pripremi lijeka za liječenje bolesti izabrane iz skupine koja obuhvaća shizofreniju, shizofrenoformni poremećaj, shizoafektivni poremećaj, deluzije, kratki psihotični poremećaj, podijeljeni psihotični poremećaj i maniju kod bipolarnog poremećaja.
The antibody or antigen-binding fragment thereof of any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof is formulated for topical, intraocular, oral, nasal, rectal or parental administration. 
Sastav prema zahtjevu 18, naznačen time, da se formulira za sljedeće primjene: topikalna, intraokularna, oralna, nazalna, rektalna ili parentalna.
is a bicyclic ring system selected from the group consisting of tetrahydroisoquinolinyl, tetrahydroquinolinyl, indolyl, dihydroindolyl, indazolyl, dihydroindazolyl, and pyrrolopyridinyl; wherein said bicyclic ring system may be substituted by 1 to 3 groups selected from the group consisting of C1-C6alkyl, substituted C1-C6alkyl, C3-C7cycloalkyl, halo, hydroxyl, oxo, amide, carboxylic acid, —C(O)Ra, —SO2Ra, arylalkyl, —(C1-C3alkyl)aryloxy, aryl, heteroaryl and C1-C4alkoxy, in which each Ra is independently C1-C6alkyl, substituted C1-C6alkyl or unsubstituted C3-C7cycloalkyl; 
R, je biciklički sustav prstena, kojeg se bira iz skupine koju čine tetrahidroizokinolinil, tetrahidrokinolinil, indolil, dihidroindolil, indazolil, dihidroindazolil, te pirolopiridinil; gdje navedeni biciklički sustav prstena može biti supstituiran s 1 do 3 skupine, koje se bira iz skupine koju čine Cy-Csalkil, supstituirani C,-Csalkil, C32-C;cikloalkil, halogen, hidroksil, okso, amid, karboksilna kiselina, -C(O)R,, - SO>R,, arilalkil, (C,-Csalkil)ariloksi, aril, heteroaril i C,-C,alkoksi, gdje je svaki R, neovisno C,-Csalkil, supstituirani C;-Csalkil ili nesupstituirani C3-Crcikloalkil; ili njegova farmaceutski prihvatljiva sol.
A compound of formula (I) or a physiologically acceptable solvate thereof for use in the treatment of patients according to claim 5, wherein the inflammatory and/or allergic condition is allergic dermatitis. 
Spoj formule (1), ili njegov fiziološki prihvatljiv solvat, namijenjen upotrebi u liječenju pacijenata u skladu s patentnim zahtjevom 5, naznačen time što upalno i/ili alergijsko stanje je alergijski dermatitis.
In certain embodiments, double-stranded short interfering nucleic acid (siNA) molecules are provided, wherein the molecule has a sense strand and an antisense strand and comprises formula (A): 
Pripravak, naznačen time, da sadržava molekulu s dvolančanom kratkom interferirajućom nukleimskom kiselinom (SINA) u skladu s patentnim zahtjevom 1 i farmaceutski prihvatljiv nosač ili razrjeđivač.
An isolated polypeptide comprising an amino acid sequence having at least 85%, more preferably at least 90%, even more preferably at least 95%, most preferred 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 4. 
HR P20170193 T1 PATENTNI ZAHTJEVI Imunogenični sastav 1li cjepivo sadrži izolirani polipeptid koji ima najmanje 85% identičan slijed aminokiselinskom slijedu kako je navedeno u SEQ ID NO:4 i farmaceutski prihvatljivi nosač ili ekscipijens.
ADM antibody or an adrenomedullin antibody fragment or ADM non-IG scaffold for use in therapy of a chronic or acute disease or acute condition of a patient according to any of the embodiments 1 to 12 to be used in combination with vasopressors e.g. catecholamine and/or fluids administered intravenously. 
Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 1 do 14, za uporabu u kombinaciji s katekolaminom i/ ili fluidima koji se primjenjuju intravenozno.
In some embodiments, Ring A is a 5-membered heterocyclic ring. 
U nekim oblicima, Prsten A je 5-člani heterociklički rsten.
Fold in the flour and mix thoroughly. 
Dodati brašno 1 temeljito izmiješati.
The composition of claim 15, wherein the second therapeutic agent is an azole, a polyene, a purine or pyrimidine nucleotide inhibitor, a pneumocandin or echinocandin derivative, a protein elongation factor inhibitor, a chitin inhibitor, a mannan inhibitor, a bactericidal or permeability-inducing (BPI) protein product, or an immunomodulating agent. 
Kompozicija prema patentnom zahtjevu 15, naznačena time, što je drugi terapeutski agens azol, polien, inhibitor purinskih ili pirimidinskih nukleotida, derivat pneumokandina ili ehinokandina, inhibitor elongacionog faktora proteina, inhibitor hitina, inhibitor manana, baktericidni ili proteinski proizvod koji inducira permeabilnost (BPI), ili imunomodulirajući agens.
Set (kit) consisting of separate packs of 
Komplet (kit) naznačen time da sadrži zasebna pakiranja
The use of claim 5, wherein the medicament improves H2O2-induced injury of PC12 cells, improves glutamic acid-induced injury of PC12 cells, inhibits expression or excretion of ICAM-1 by endothelial cells in cerebral vessels and/or inhibits the transformation of T- and B-lymphocytes. 
Analgecine za uporabu kao lijek prema zahtjevu 1, gdje analgecine poboljšava H;O,-induciranu ozljedu PC12 stanica ili analgecine poboljšava ozljedu PC12 stanice induciranu glutaminskom kiselinom ili analgecine inhibira ekspresiju 1li izlučivanje ICAM-1 iz endotelnih stanica u žilama mozga ili analgecine inhibira transformaciju T- i B-limfocita.
The process according to claim 3, wherein the polymethacrylate has an oxygen content of at least 25% by weight. 
Postupak prema zahtjevu 3, naznačen time što polimetakrilat ima sadržaj kisika od najmanje 25 masenih %.
The pneumatic precision seed drill in accordance with claim 1 wherein the separating plates (4, 5) can be connected in pairs via fasteners (42) in such a way that the holes (17, 18, 19, 20) provided in facing separating plates (4, 5) are aligned offset to one another in the assembled condition. 
Srce za sijanje u skladu sa patentnim zahtjevom 1 ili 2, naznačeno time da ploče (4,5) za odvajanje mogu biti povezane u parovima preko kopči (42) na takav način da su rupe (17,18,19,20) koje su osigurane u pločama (4,5) za odvajanje koje su okrenute jedna ka drugoj poredane nagnuto jedna ka drugoj u sastavljenom stanju.